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Abstract: The pyridoacridine alkaloids kuanoniamines A and C were isolated together with 
24α-methylcholestanol, p-hydroxybenzaldehyde, p-hydroxybenzoic acid, phenylacetic acid 
and 3-formylindole from the ethyl acetate extract of the marine sponge Oceanapia 
sagittaria (Sollas), collected from the Gulf of Thailand. Kuanoniamines A and C were 
evaluated for their effect on the growth of five human tumour and a non-tumour cell lines, 
as well as on the proliferation of human lymphocytes. Kuanoniamine A was found to be a 
potent growth inhibitor of all the tumour and a non-tumour cell lines while kuanoniamine C 
was less potent but showed high selectivity toward the estrogen dependent (ER+) breast 
cancer cell line. Kuanoniamine A has shown to be a more potent inhibitor of DNA synthesis 
than kuanoniamine C. Kuanoniamine A was also found to cause an extensive reduction of the 
MCF-7 cells in G2/M phase as well as an increase in the apoptotic cells. Mar. Drugs 2007, 5                                                  
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1. Introduction 
 
Species of Oceanapia are common, with more than 50 nominal species recorded for the Indo-west 
Pacific region alone, relatively abundant in both soft and hard substrates, and widely distributed [1]. 
However, the chemistry of this genus seems to vary significantly. Though a majority of the compounds 
isolated from the marine sponges of this genus are alkaloids, several non alkaloidal constituents have 
also been isolated. Thus, while an antifungal bis α,ϖ amino alcohol glycoside, oceanapiside, was 
reported from O. phillipensis, collected from Southern Australia [2], Oceanapia sp., collected from the 
Northwest coast of Australia, furnished a hybrid α,ϖ-bifunctionalized sphingoid tetrahydroquinoline 
β-glucoside [3]. Capon et al. [4, 5] reported the isolation of nematocidal bisthiocyanates from the 
ethanol extract of Oceanapia sp., also collected from Australia. Matsugana et al. have reported 
isolation of a bioactive acetylenic acid from the lipophillic extract of the Japanese collection of 
Oceanapia sp. [6]. On the other hand, most of the alkaloids reported from the genus Oceanapia were 
pyridoacridine alkaloids except for oceanapamine, a sesquiterpene alkaloid from specimens of 
Oceanapia sp., collected from Palawan island, the Phillipines [7] and the phloeodictynes from O. 
fistulusa from the Eastern coast of New Caledonia [8]. 
The most studied pyridoacridine alkaloids are the kuanoniamines. So far, only kuanoniamines C 
and D have been reported from the sponges of the genus Oceanapia. While kuanoniamine C, together 
with sagitol, were found to be the major constituents of the marine sponge O. sagitaria from Palau [9], 
kuanoniamines C and D and their N-acetyl derivative were also isolated from the Micronesian sponge 
Oceanapia sp. [10]. Interestingly, kuanoniamine C was shown to be produced by the sponge cells and 
not by intracellular symbiotic organisms of O. sagittaria [11]. Schupp et al. [12] have found that 
amounts of kuanoniamines C and D, the major secondary metabolites of the Micronesian Oceanapia 
sp, increased sharply from the basal root to the capitum. These findings let them to conclude that these 
alkaloids had ecological implication to this sponge. Recently, the alkaloid petrosamine B, an inhibitor 
of the Helicobacter pylori enzyme aspartyl semialdehydedehydrogenase, was isolated from the 
methanol extract of the Australia sponge Oceanapia sp. [13]. 
In the course of our investigation on bioactive compounds from the marine sponges from the Gulf 
of Thailand, we have isolated 24α-methylcholestanol (1),  p-hydroxybenzaldehyde (2),  p-
hydroxybenzoic acid (3), phenylacetic acid (4), 3-formylindole (5), kuanoniamine A (6) and 
kuanoniamine C (7) from the ethyl acetate extract of the marine sponge Oceanapia sagittaria (Sollas), 
collected near Koh Samed island in the Gulf of Thailand (Figure 1). We have also investigated the 
effect of kuanoniamines A (6) and C (7) on the growth of five human tumour cell lines: MCF-7 (breast 
carcinoma, estrogen–dependent ER+), MDA-MB-231 (breast carcinoma, estrogen–independent ER-), 
SF-268 (glioma), NCI-H460 (non small cell lung cancer), UACC-62 (melanoma), and a non-tumour 
human cell line MRC-5 (diploid embryonic lung fibroblast), as well as on the proliferation of 
peripheral human lymphocytes. As kuanoniamines A and C were found to be potent growth inhibitors Mar. Drugs 2007, 5                                                  
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of the MCF-7 cells, they were also evaluated for their effect on DNA biosynthesis and MTT-reducing 
capacity as well as on a cell cycle progression and apoptosis of these cells. 
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Figure 1. Structure of compounds 1-7. 
 
2. Results and Discussion 
 
Kuanoniamine A (6) has been initially reported, together with kuanonamine C, from an unidentified 
purple colonial tunicate and its prosobranch mollusc predator Chelynotus semprei and was found to 
inhibit the proliferation of KB (human pharyngeal cancer) cell lines in vitro at an IC50 of 1 μg/ml [14]. 
Though a total synthesis of kuanoniamine A has been proposed [15], to our knowledge it has never 
been reported from the marine sponges of the genus Oceanapia. On the contrary, kuanoniamine C (7) 
has been reported later from Oceanapia sagittaria [9, 11] and from the Micronesian sponge Oceanapia 
sp. [12] and was found to exhibit significant in vitro cytotoxicity to Hela and MONO-MAC 6 tumour 
cells [10]. On the other hand, 24α-methylcholestanol (1) is one of the common marine sterols while p-
hydroxybenzaldehyde (2), p-hydroxybenzoic acid (3), phenylacetic acid (4) and 3-formylindole (5) are 
probably degradation products of the secondary metabolites and have been commonly found in many 
marine sponges.  
The structures of 24α-methylcholestanol (1), 3-formylindole (5), kuanoniamine A (6) and 
kuanoniamine C (7) were established by 
1H, 
13CNMR, DEPTs, COSY, HSQC, HMBC, NOESY 
spectroscopy and HRMS as well as by comparison of their proton and carbon chemical shifts and other 
physical data with those reported previously [14]. Mar. Drugs 2007, 5                                                  
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The effect of kuanoniamine A (6) and kuanoniamine C (7) on the in vitro growth of five human 
tumour cell lines: MCF-7 (ER+), MDA-MB-231 (ER-), SF-268, NCI-H460, UACC-62, and on the 
non-tumour cell line MRC-5 was evaluated after a continuous exposure of 48 h. Results given in 
concentrations that were able to cause 50% of cell growth inhibition (GI50) are summarized in Table 1. 
Kuanoniamine A (6) was found to potently inhibit the growth of all the five human tumour cell lines, 
as demonstrated by its low GI50 values (≤ 5 µM). This potent effect was also observed for the non-
tumour fibroblast cell line MRC-5. Kuanoniamine C (7) also inhibited the growth of all these tumour 
cell lines. However, its effect was at least ten times less potent than that observed for kuanoniamine A 
for MDA-MB-231, SF-268, NCI-H460 and UACC-62. Interestingly, the low value of the GI50 of 
kuanoniamine C on MCF-7 (0.81 ± 0.11 µM) indicates a high selectivity of this estrogen dependent 
(ER +) breast cancer cell line to this compound. Since the growth inhibitory effect of kuanoniamine C 
was less intense on the estrogen independent (ER-) MDA-MB-231, it is possible that the estrogen 
receptors could be involved in this antiproliferative effect. However more studies are needed to 
confirm the possible antiestrogenic effect of kuanoniamine C.  
Table 1. Effect of kuanoniamine A (6) and kuanoniamine C (7) on the growth of 
human tumour and non-tumour cell lines *. 
      _____________________________________________________________________________ 
       GI50 (μM) 
_____________________________________________________________________________ 
Compounds                  MCF-7           MDA-MB-231   NCI-H460       SF-268         UACC-62         MRC-5 
_____________________________________________________________________________ 
Kuanoniamine A (6)    0.12 ± 0.07     0.73 ± 0.27          0.91 ± 0.18     4.67 ± 0.20      1.83
a               0.58 ± 0.15 
 
Kuanoniamine C (7)    0.81 ± 0.11     10.23 ± 3.35       21.50 ± 2.44    33.16
a              15.78
a             ND 
____________________________________________________________________________________________ 
* Results are given in concentrations that were able to cause 50% of cell growth inhibition (GI50) after 
a continuous exposure of 48 h and represent means ± SEM of 3-5 independent experiments performed 
in duplicate.
 aResults from one or two independent experiments performed in duplicate. Doxorubicin 
was used as positive control, GI50: MCF-7 = 42.8 ± 8.2 nM; MDA-MB-231 = 10.86 ± 1.28 nM; NCI-
H460 = 94.0 ± 8.7 nM; SF-268 = 94.0 ± 7.0; UACC-62 = 94.0 ± 9.4 nM.  
 
As both kuanoniamine A (6) and kuanoniamine C (7) were found to be potent inhibitors of the 
MCF-7 cells, we have selected this breast cancer cell line to further characterize the growth inhibitory 
effect of the two compounds. We first evaluated their capacity to interfere with the biosynthesis of 
DNA by exposing the exponential growing MCF-7 cells to a range of increasing concentrations of 
kuanoniamine A (6) and kuanoniamine C (7), below and above their GI50 (0.04 - 86.51 μM and 0.03 - 
66.84 μM, respectively) for 6, 12, 24 and 48 h and the DNA synthesis was quantified by thymidine 
incorporation (Figure 2). The dose-response curve showed that kuanoniamine A (6) dramatically 
affected DNA synthesis, even at concentrations as low as 0.08 μM, which were associated with a 
decrease in thymidine incorporation of more than 60% when compared with untreatead control cells. It Mar. Drugs 2007, 5                                                  
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was also found that the effect on DNA synthesis was mainly dependent on the concentration of 
kuanoniamine A (6) rather than on the exposure time. On the contrary, the effect of kuanoniamine C 
(7) was found to be dependent either on the concentration or the exposure time. Although an inhibition 
of DNA synthesis was also observed with kuanoniamine C (7), an interesting stimulatory effect was 
detected at low concentrations and exposure periods of 6 and 12 h. A maximum stimulation of 130% 
was reached after 6 h of treatment with 0.26 and 0.52 μM. This biphasic effect in DNA synthesis of 
ER (+) MCF-7 cells, expressed by a stimulatory effect at low concentrations and an inhibitory effect at 
high concentrations, resembles the behaviour described for phytoestrogens on ER (+) breast cancer 
cells [16, 17].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Time and dose-dependent curves of kuanoniamine A (6) and kuanoniamine C (7) in 
DNA synthesis of MCF-7 cells determined by [
3H]-thymidine incorporation assay. 
Results are the mean ± SEM of four replicates from a representative experiment. 
 
In order to get more insight on the mechanism of kuanoniamine A (6) and kuanoniamine C (7), both 
compounds were evaluated for their effect on the capacity of MCF-7 cells to reduce MTT (Figure 3).  
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Figure 3. Time and dose-dependent curves of kuanoniamine A (6) and kuanoniamine C (7) in MTT 
reduction capacity of MCF-7 cells. Results are the mean ± SEM of three replicates from a 
representative experiment. 
 
Kuanoniamine A (6) was shown to be more drastic and more dependent on the exposure time than 
kuanoniamine C (7). Cell viability was dramatically affected even when treatments with low 
concentrations of kuanoniamine A (6) and in short periods of time. A decrease of viability to 70% was 
detected after 6 h of exposure at the lowest concentration studied (0.04 µM) and exposure of 24 h and 
48 h were associated with a dramatic falls of the viability. This lost of viability is in accordance with 
the drastic effect observed in DNA synthesis after these treatments. However the cells whose DNA 
synthesis was dramatically affected are still viable and capable of reducing MTT, similar to those 
treated with concentrations of 0.06 µM. On the contrary, kuanoniamine C (7) did not affect the cells so 
drastically as kuanoniamine A (6) and 70% of the cells remained viable and with a capacity to reduce 
MTT, even after treatments with concentrations near the GI50 and exposure time of 24 and 48 h. 
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We have found also that the effect of kuanoniamine A (6) and kuanoniamine C (7) on the protein 
content of MCF-7 cells (Figure 4) was comparable to that observed with MTT, as can be concluded by 
the similarity between the curves slop.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Time and dose dependent curves of kuanoniamine A (6) and kuanoniamine C (7) on the cell 
growth of MCF-7 cells determined by protein content (SRB) assay. Results are the mean ± SEM of 
three replicates from a representative experiment. 
 
With kuanoniamine A (6), the loss of cellular protein content falls immediately for the values below 
70% after the exposure time as low as 6 h. This effect was found to be significantly dependent on the 
exposure time. On the contrary, the effect of kuanoniamine C (7) was found to be less intense and the 
cellular protein content was stable for almost all the treatments. 
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C (7) and the distribution of cells in each phase of the cell cycle was determined by flow cytometric 
analysis of DNA content and the results are shown in Figure 5.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Effect of kuanoniamine A (6) and kuanoniamine C (7) on the cell cycle of MCF-7 cells. 
Untreated control cells and cells treated with 0.34 mM of kuanoniamine A (6) for 24 h and treated with 
4.18 and 8.35 mM of kuanoniamine C (7) for 24 and 48 h, stained with propidium iodide (PI) and 
analyzed by flow cytometry for DNA content. 
 
From this figure, it can be concluded that an extensive reduction of cells in G2/M phase (5.71%) 
with a consequent accumulation of cells in G1 phase (81.41%) and a reduction on the cellular fraction 
in S phase (12.88%) was observed in cells treated with 0.34 µM of kuanoniamine A (6) for 24 h when 
compared with these phases of untreated control cells (12.17%, 70.04% and 17.79 %, respectively). In 
contrast to what has been observed for kuanoniamine A (6), no considerable effect was detected in 
cells treated with 4.18 and 8.35 µM of kuanoniamine C (7) for 24 h. However, the increase in the 
exposure time to 48 h has also led to an increase in the number of cells in G1 (73.34%) and a decrease 
of G2/M-phase (8.89%) and S-phase (17.77%) population when compared to control cells (64.01%, 
13.28% and 22.71%, respectively). It is not surprising that both compounds have caused the reduction 
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of the S phase cellular fraction as the concentrations used in these experiments were found to inhibit 
severely DNA synthesis. 
During the experiments we have observed that the proliferative effect of kuanoniamine C (7), 
associated with treatments with low concentrations and short exposure times, as previously detected by 
thymidine incorporation, was not accompanied by an enhancement of MTT reducing activity or by an 
increase of cellular protein content. This observation can be explained by a low sensitivity of the MTT 
and SRB assay for the analysis of cell proliferation when compared with the 
3H-thymidine uptake 
method incorporation.  
In order to investigate if the growth inhibitory effect of the kuanoniamine A (6) and kuanoniamine 
C (7) on MCF-7 was exerted through the involvement of apoptosis, the cells were treated for 24 h with 
inhibitory concentrations of kuanoniamine A (0.5, 1.0 and 2.5 µM) and kuanoniamine C (1.0 and 2.5 
µM) and then evaluated for DNA fragmentation by the TUNEL assay. With this method, a significant 
increase in the number of apoptotic cells was detected after treatment with kuanoniamine A (6.19 % 
and 7.2 % for 0.5 and 1.0 µM, respectively) as well as with kuanoniamine C (5.21 % and 9.25 % for 
1.0 and 2.5 µM, respectively) when compared with untreated control cells (1.41 %). This observation 
led to a conclusion that the antiproliferative effects of these two compounds were in part associated 
with apoptosis. Although treatments with 0.5 and 1.0 µM of kuanoniamine A (6) for 24 h were 
associated with an inhibition of DNA synthesis, cell viability (as measured by the trypan blue assay, 
Figure 6) remained moderately high (≥70%), which allowed apoptosis estimation. On the contrary, the 
concentration of 2.5 µM showed to be very toxic to cells causing the drastic decrease of viability for 
the values of 35.7% impairing apoptosis evaluation.  
 
 
 
 
 
 
 
 
 
 
Figure 6. Effect of kuanoniamine A (6) on the viability of MCF-7 cells determined by trypan blue 
exclusion assay. Cells were exposed to 0.5, 1 and 2.5 μM kuanoniamine A (6) for 24 h. 
 
Finally, kuanoniamine A (6) and kuanoniamine C (7) were evaluated for their effect on the 
mitogenic response of peripheral human lymphocytes to PHA. Both compounds were shown to inhibit 
the proliferation of human lymphocytes (Table 2). Kuanoniamine A (6) was found to be a very potent 
inhibitor, exhibiting a IC50 value in the same order of cyclosporin A (1.50 μM  versus 1.1 μM, 
respectively).  
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Table 2. Effect of kuanoniamine A (6) and kuanoniamine C (7) on the proliferation of human 
lymphocytes induced by PHA.* 
______________________________________________________________________________ 
Compounds        IC50 (μM) 
______________________________________________________________________________ 
 
kuanoniamine A (6)      1.50
a 
 
kuanoniamine B (7)       21.07  ±  1.16 
______________________________________________________________________________ 
* Results are given in concentration that caused 50% inhibition of proliferation (IC50) after a 
continuous exposure of 96 h and represent means ± SEM of 3 experiments performed in duplicate. 
Cyclosporin A was used as positive control, IC50 = 1,1± 0.24 μM. 
aResults from two experiments 
performed in duplicate. 
 
3. Conclusion 
The pyridoacridine alkaloids kuanoniamines A and C, isolated from the Thai collection of the 
marine sponge Oceanapia sagittaria (Sollas), have been evaluated for their cytotoxic effect against 
five human tumour cell lines and one human non-tumour cell lines by the SRB method. Kuanoniamine 
A (6) has shown to be a potent growth inhibitor of all the human tumor cell lines as well as the non-
tumour cell line. Though kuanoniamine C (7) was found to be much less potent than kuanoniamine A, 
it was found to possess a high selectivity toward the estrogen dependent (ER+) breast cancer cell line. 
As the inhibitory effect of kuanoniamine C on the estrogen independent (ER-) breast cancer cell line 
was less intense than that on the estrogen dependent (ER+) counterpart, it was suggested that the 
estrogen receptors could be involved in this antiproliferative effect. Using [
3H]  thymidine 
incorporation assay, it was found that the DNA synthesis of the MCF-7 cells was dramatically affected 
by kuanoniamine A and it was dependent on the concentration of kuanoniamine A rather and the 
exposure time. On the other hand, kuanoniamine C showed a stimulatory effect at low concentration 
but an inhibitory effect at high concentrations. The biphasic effect of kuanoniamine C on DNA 
synthesis of the MCF-cells resembled with that caused by phytoestrogens on the estrogen dependent 
breast cancer cells. Using the MTT-reducing capacity assay, it was found that the effect of 
kuanoniamine A was much more potent than kuanoniamine C on the cell viability of the MCF-7 cells 
and this loss of cell viability caused by kuanoniamine A was in accordance with its drastic effect on 
DNA synthesis observed after these treatments. Flow cytometric analysis of the DNA content has 
showed that kuanoniamine A has caused an extensive reduction of the MCF-7 cells in G2/M phase 
with a consequent accumulation of the cells in G1 phase and a reduction of the cellular fraction in S 
phase while kuanoniamine C showed no considerable effect on these cells. Using the TUNEL assay to 
measure a prelytic DNA fragmentation, it was found that both kuanoniamines A and C have caused an 
increase of the apoptotic cells, indicating that their antiproliferative effects on the MCF-7 cancer cell 
lines could in part be related to the phenomenon of apoptosis. However, more studies are needed to 
confirm and characterize the capacity of these compounds in inducing apoptosis since DNA cleavage Mar. Drugs 2007, 5                                                  
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may also accompany necrosis which is another mechanism of cell death. Contrary to apoptosis, 
necrotic cell death is often associated with an in vivo extensive tissue damage which, in turn, results in 
an intense inflammatory response. It is advocated that the inflammatory component of the necrotic cell 
death could have the potential advantage of stimulating an immune response to the tumor and a 
balance between apoptotic and necrotic cell death has been referred as an advantage on cancer therapy 
[22]. 
 
4. Experimental 
 
4.1. General 
Melting points were recorded on a Bock monoscope and are uncorrected. Rotations were 
determined on a Polax-2L instrument. Si gel for chromatography was silica gel 60 (0.2-0.5 mm Merck) 
for analytical work and for preparative work TLC silica gel 60 GF 254 Merck. 
 
4.2. Animal material 
Oceanapia sagittaria (Sollas, 1902), order Haplosclerida, family Oceanapiidae, was collected by 
Scuba diving in the Gulf of Thailand near Koh Samed (3 meter depth) in April 2005 and frozen 
immediately at -20ºC prior to extraction. The sponge material was identified by Dr. Sumaitt 
Putchakarn and the voucher registered as BIMS-I 2004 was deposited at Bangsaen Institute of Marine 
Science, Burapha University, Thailand. 
 
4.3. Extraction, isolation and characterization of the constituents 
The sample (3.5 kg net weight) was thawed, homogenized with EtOH (7L), allowed to stand for 24 
h in the dark chamber and filtered. The residue on the filter paper was again extracted with EtOH 
(2x7L), the aqueous alcoholic extracts were combined, evaporated at reduced pressure to give ca. 800 
ml and extracted with EtOAc (3 x 1L). The EtOAc extracts were combined and concentrated at 
reduced pressure to give a crude EtOAc extract (13.1g). 
The crude EtOAc extract (13.1 g) was applied over a flash chromatography column of Si gel 60 
(150g) and eluted with a solvent gradient system of petrol-CHCl3, CHCl3, CHCl3,-MeOH, EtOAc and 
MeOH, with 200 ml fractions being collected as follows: Frs. 1-2 (petrol-CHCl3,1:4), 3-7 (CHCl3), 8-
17 (CHCl3,-MeOH, 49:1), 18-22 CHCl3,-MeOH, 19:1), 23-24 (CHCl3,-MeOH, 9:1), 25-26 (EtOAc), 
27-30 (MeOH). Frs.3-4 were combined (2.6 g) and recrystallized from a mixture of petrol and CHCl3 
to give white crystal of 24α-methylcholestanol (1, 436 mg). Frs. 6-7 were combined (870 mg) and 
chromatographed over Si Gel 60 (20 g) and eluted with petrol-CHCl3, CHCl3-Me2CO, and CHCl3-
MeOH, 200 ml subfractions were collected as follows: Sfrs. 1-7 (petrol-CHCl3, 2:3), 8-15 (petrol-
CHCl3, 1:4), 16-24 (CHCl3), 25-30 (CHCl3-Me2CO, 19:1), 31-34 (CHCl3-Me2CO, 9:1), 35-38 (CHCl3-
Me2CO, 4:1), 39-43 (CHCl3-Me2CO, 3:2), 44-45 (MeOH). Sfrs. 3-6 were combined (156 mg) and 
purified by TLC (Si gel, CHCl3) to give 33.2 mg of a mixture of p-hydroxybenzoic acid (3) and 
phenylacetic acid (4). Subfrs. 7-15 were combined and purified by TLC (Si gel, CHCl3-Me2CO-
HCO2H, 18:1:0.1) to give kuanoniamine A (6, 20 mg). Frs. 8-10 were combined (390 mg) and purified Mar. Drugs 2007, 5                                                  
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by TLC (Si gel, CHCl3, Me2CO, HCO2H, 95:5:0.1) to give p-hydroxybenzaldehyde (2, 15.7 mg) and 
3-formylindole (5, 18.6 mg). Frs. 11-13 were combined (346 mg) and purified by TLC (Si gel, CHCl3, 
MeOH, HCO2H, 98:2:0.1) to give kuanoniamine A (6, 32 mg). Frs.20-22 were combined (355 mg) and 
applied over a flash chromatography column of ODS gel (10g) and eluted with a gradient system of 
MeOH-H2O and MeOH-CHCl3-H2O, 100 ml fractions being eluted as follows: sfrs 1-2 (MeOH-H2O, 
7:3), 3-4 (MeOH-H2O, 4:1), 5-6 (MeOH-H2O, 9:1), 7-10 (MeOH), 11-14 MeOH-CHCl3-H2O, 7:3:0.5). 
Sfrs. 5-6 were combined (81 mg) and recrystallized from a mixture of CHCl3 and Me2CO to give 
yellow crystals of kuanonamine C (7, 44 mg). 
 
4.4. Biological activity 
 
4.4.1. Material and Methods 
 
4.4.1.1. Reagents  
 
Fetal bovine serum (FBS), L-glutamine, phosphate buffered saline (PBS) and trypsin were from 
Gibco Invitrogen Co. (Scotland, UK). RPMI-1640 medium were from Cambrex (New Jersey, USA). 
Acetic acid, cyclosporin A, dimethyl sulfoxide (DMSO), doxorubicin, ethylenediaminetetraacetic acid 
(EDTA), Histopaque®-1077, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 
penicillin, phytohemagglutinin (PHA), propidium iodide (PI), RNase, streptomycin, sulforhodamine B 
(SRB), Triton X-100, trypan blue were from SigmaChemical Co (Saint Louis, USA). Magnesium 
chloride, paraformaldehyde, tricloroacetic acid (TCA), Tris, sodium citrate and sodium dodecyl 
sulphate (SDS) were sourced from Merck (Darmstadt, Germany). Dimethylformamide (DMF) from 
Romil Chemicals (Cambridge, England). Heparin was sourced from Sanofi Winthrop Inc. (Paris, 
France). Vectashield, Vectashield containing DAPI (0.5 µg/ml) were from Vector Laboratories (UK). 
FACSCalibur flow was from Becton Dickinson (Mountain View, CA), [
3H]-thymidine from 
Amersham (Illinois, USA) and scintillation liquid from PerkinElmer (Boston, USA). 
 
4.4.1.2. Samples 
Stocks solutions of kuanoniamine A (6) and kuanoniamine C (7) were prepared in DMSO and kept 
at −20°C. Appropriate dilutions of the compounds were freshly prepared just prior the assays.  
 
4.4.1.3. Cell cultures 
Five human tumour cell lines, MCF-7 (breast adenocarcinoma, estrogen-dependent ER (+)), MDA-
MB-231 (breast adenocarcinoma, estrogen-independent ER (-)), NCI-H460 (non-small cell lung 
cancer), SF-268 (glioma) and UACC-62 (melanoma) and one non-tumour cell line, MRC-5 (diploid 
embryonic lung fibroblast) were used. MCF-7, MDA-MB-231 and MRC-5 were obtained from the 
European Collection of Cell Cultures (ECACC, Salisbury, UK) while NCI-H460, SF-268 and UACC-
62 cell lines were provided by the National Cancer Institute (NCI, Bethesda, U.S.A.). Cells, growing 
as monolayer, were routinely maintained in RPMI-1640 medium supplemented with 5% heat-Mar. Drugs 2007, 5                                                  
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inactivated FBS, 2 mM glutamine and antibiotics (penicillin 100 U/ml, streptomycin 100 μg/ml), at 
37°C in a humidified atmosphere containing 5% CO2. Exponentially growing cells were obtained by 
plating 1.5×10
5cells/ml for MCF-7, MDA-MB-231, SF-268 and MRC-5, 1.0 × 10
5cells/ml for UACC-
62 and 0.75 × 10
4cells/ml for NCI-H460, followed by 24 h incubation. The effect of the vehicle 
solvent (DMSO) on the growth of these cell lines was evaluated in all the experiments by exposing 
untreated control cells to the maximum concentration (0.5%) of DMSO used in each assay. 
 
4.4.1.4. Cells growth assay 
The effects of the kuanoniamine A (6) and kuanoniamine C (7) on the growth of human tumour and 
non-tumour cell lines were evaluated according to the procedure adopted by the National Cancer 
Institute (NCI, USA) in the “In vitro Anticancer Drug Discovery Screen” that uses the protein-binding 
dye sulforhodamine B to assess cell growth [18, 19]. Exponentially growing cells were then exposed 
for 48 h to five serial concentrations of kuanoniamine A (0.14; 0.69; 3.46; 17.30 and 86.51 μM) and 
kuanoniamine C (0.11; 0.53; 2.67; 13.37 and 66.84 μM) that were starting from a maximum of 25 
μg/ml (86.51 μM and 66.84 μM, respectively). 
Following this exposure period adherent cells were fixed in situ with 50% TCA, washed with 
distillated water and stained with 0.4% SRB solubilized in 1% acetic acid. The bound stain was 
solubilized in 10 mM Tris and the absorbance was measured at 492 nm in a microplate reader (Bio-tek 
Instruments Inc., Powerwave XS, Wincoski, USA). For each cell line a dose-response curve was 
obtained and the growth inhibition of 50% (GI50), corresponding to the concentration of kuanoniamine 
A and kuanoniamine C that inhibited 50% of the net cell growth was calculated as described elsewhere 
[19]. Doxorubicin was used as a positive control and tested in the same manner.  
 
4.4.1.5. Lymphocytes proliferation assay 
The effect of kuanoniamine A and kuanoniamine C on the mitogenic response of human 
lymphocytes to PHA (10 μg/ml) was evaluated using a modified version of the colorimetric MTT-
assay [20]. This has been intensively described elsewhere by our group [21]. Briefly, mononuclear 
cells, isolated from heparinized peripheral blood of healthy volunteers by Histopaque®-1077 density 
centrifugation, were adjusted to 2–3 x 10
6 cells/ml in RPMI-1640 supplemented with 10% FBS, 2 mM 
glutamine and antibiotics (penicillin 100 U/ml, streptomycin 100 μg/ml). They were then harvested in 
96-well plates and exposed for 4 days to seven serial concentrations of kuanoniamine A (0.12; 0.36; 
1.07; 3.20; 9.61; 28.84 and 86.51 μM) and of kuanoniamine C (0.09; 0.28; 0.83; 2.48; 7.43; 22.28 and 
66.84 μM) at 37 ºC. Following this incubation period, the MTT solution (1 mg/ml) was added and 
plates were incubated for more 4 h.  The water insoluble formazan dye formed was solubilized with 
SDS/DMF solution (20% SDS in a 50% solution of DMF, pH 4.7) overnight at 37 °C.  The absorbance 
of the colored solution was then measured in a microplate reader (Bio-tek Instruments Inc., 
Powerwave XS, Wincoski, USA) at 550 nm. The concentration of compounds that inhibited 50% of 
lymphocyte proliferation (IC50) was calculated by the curve obtained (% inhibition versus 
concentration). Cyclosporin A was used as a positive control. Seven serial concentrations (0.0014; 
0.01; 0.04; 0.18; 0.89; 4.44 and 22.20 µM) were studied in the same manner. Mar. Drugs 2007, 5                                                  
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4.4.1.6. Evaluation of MCF-7 cells growth by [
3H] thymidine incorporation, SRB and MTT assays   
MCF-7 cells growing exponentially in 96-well plates were treated with a range of concentrations of 
kuanoniamine A (0.04; 0.08; 0.17; 0.34; 0.68; 1.35; 2.70; 5.41; 10.81; 21.63; 43.26 and 86.51 μM) and 
of kuanoniamine C (0.03; 0.07; 0.13; 0.26; 0.52; 1.04; 2.09; 4.18; 8.36; 16.71; 33.42 and 66.84 μM) 
for 6, 12, 24 and 48 h. Following this incubation period cell growth was assessed by [
3H]-thymidine 
incorporation, MTT and SRB assays. In the [
3H]-thymidine incorporation assay cells were further 
incubated with 1 μCi of [
3H] thymidine for 4 h. Pulsed cells were then harvested on a glass filter 102 x 
256 mm (Skatron, Norway) using a semiautomatic cell harvester (Skatron Instruments, Norway) and 
allowed to dry. Incorporation of radioactive thymidine was determined in a scintillation counter (LS 
6500, Beckman Instruments, CA and USA) and defined by comparing the arithmetic mean of counts 
per minute (cpm) of treated cells with that of untreated control cells.  
In the MTT assay, MTT was added (5 mg/ml) and cells were incubated for a further 4 h. Formazan 
product were solubilized with SDS/DMF solution overnight at 37ºC. Absorbance was measured at 550 
nm in the microplate reader. The percentage of MTT reduction was calculated comparing the 
absorbance of treated cells to that of untreated control cells. 
In the SRB assay adherent cells were fixed in situ with 50% TCA, washed with distillated water and 
stained with the protein binding dye (0.4% SRB) solubilized in 1% acetic acid, and then the bound 
stain was solubilized in 10 mM Tris, as described [18]. The bound stain was solubilized and the 
absorbance was measure at 492 nm in the microplate reader.  
 
4.4.1.7. Cell cycle analysis 
MCF-7 cells growing exponentially in 25 cm
2 flasks were treated with 0.08, 0.17, 0.34 and 0.68 μM 
of kuanoniamine A for 24 h and 4.18 and 8.35 μM of kuanoniamine C for 24 and 48 h. After 
treatment, attached cells were released by trypsinization and mixed with non-adherent cells. Cells were 
centrifuged, washed twice with PBS and fixed with 70% ice-cold ethanol. Fixed cells (1 x 10
6 
cells/ml) were resuspended in the DNA staining solution containing 50 μg/ml propidium iodide, 0.5 
mg/ml RNase in 10 mM Tris and 5 mM MgCl2. DNA cellular content was analyzed with a 
FACSCalibur flow cytometer (Becton Dickinson, Mountain View, CA) with excitation at 488 nm. 
Data was acquired in a listmode data file, gated to 30.000 events in cell cycle, using the CellQuest Pro 
software, version 4.0.2 (Becton Dickinson Mountain View, CA) included in the system. Cell cycle was 
analysed using the ModFit LT 3.0 software program (Verity Software Topsham) with an activated gate 
to eliminate aggregates (FL2-A/FL2-W). 
 
4.4.1.8. Apoptosis assay 
Fragmentation of the cellular DNA was evaluated using the In Situ Cell Death Detection Kit 
(TUNEL) Fluorescein (Boehringer Mannheim, Germany). Exponential MCF-7 cells growing on 
coverglasses in 6-well plates were exposed to 0.5 and 1.0 μM of kuanoniamine A and 1.0 and 2.5 μM 
of kuanoniamine C for 24 h. After treatment, plates were centrifuged at 2000 rpm for 5 min at room 
temperature in order to sediment non-adherent cells and fixed with 4% paraformaldehyde (in PBS) for 
1 hour at room temperature. Fixed cells were washed 4 times for 5 minutes and permeabilized (0.1% Mar. Drugs 2007, 5                                                  
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Triton X-100, 0.1% sodium citrate in distillated water) for 2 min on ice (4°C) and washed with PBS 4 
times for 5 minutes. Coverglasses were mounted in Vectashield containing 50 μg/ml PI and 0.5 μg/ml 
RNase. All preparations were observed under the fluorescence microscope (Eclipse E400, Nikon, 
Japan). The images were acquired from the photograph system ACT.2U from Nikon. Apoptotic cells 
were quantified by counting a minimum of 400 cells from at least five different random areas of the 
slide. 
 
4.4.1.9. Trypan blue exclusion assay 
Exponential MCF-7 cells growing in 6-well plates were treated with 0.5, 1.0 and 2.5 μM of 
kuanoniamine A for 24h. After treatment, attached cells were released by trypsinization and mixed 
with non-adherent cells. Cells were stained with 0.2% trypan blue and viable and non-viable cells were 
counted in a hemocytometer. Results were expressed in terms of percentage of viable cells in the total 
cell number. 
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